Lake Street analyst Frank Takkinen lowered the firm’s price target on Inotiv (NOTV) to $5 from $6 and keeps a Buy rating on the shares. Inotiv’s recovery “continues to trend favorably,” but the firm is taking a more conservative stance with its revenue and EBITDA estimates as it now believes its prior view of the recovery ramp was “too steep,” the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NOTV:
- Inotiv, Inc. Reports Improved Q2 Fiscal 2025 Results
- Inotiv, Inc. (NOTV) Q2 Earnings Cheat Sheet
- Lake Street doesn’t expect Inotiv financial impact from FDA ‘headline noise’
- Inotiv drops after FDA says phasing out animal testing of monoclonal antibodies
- Sea Pharmaceuticals announces strategic relationship with Inotiv